Vir Biotechnology Aktie
WKN DE: A2PS0P / ISIN: US92764N1028
|
25.11.2024 15:30:00
|
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida.
A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir Biotechnology’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and programs across several clinically validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125578049/en/
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Vir Biotechnology Inc Registered Shsmehr Nachrichten
|
05.08.25 |
Ausblick: Vir Biotechnology legt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
|
06.05.25 |
Ausblick: Vir Biotechnology gewährt Anlegern Blick in die Bücher (finanzen.net) |
Analysen zu Vir Biotechnology Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
| Vir Biotechnology Inc Registered Shs | 5,98 | 3,46% |
|